{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:28:33Z","timestamp":1793996913870,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA244118"],"award-info":[{"award-number":["P01 CA244118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The phase 2 SWOG S1512 trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02775851\" ext-link-type=\"uri\">NCT02775851<\/jats:ext-link>\n                    ) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the trial, evaluating the pathological complete response (pCR) rate of neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma. Secondary endpoints included clinical response rate, overall survival and toxicities. Twenty-eight eligible individuals with resectable desmoplastic melanoma received intravenous pembrolizumab (200\u2009mg) every 3 weeks three times, followed by excision. Tissue samples before treatment, at 3\u20135 weeks after treatment initiation and at the time of surgery were reviewed. The primary endpoint of pCR rate by local pathological review was 71% (95% confidence interval, 51\u201387%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), which met the prespecified endpoint. There were two (7%) grade 3 treatment-related adverse events. At three years of follow-up, four participants have died, none known to be from melanoma or adverse events. In conclusion, neoadjuvant pembrolizumab in individuals with resectable desmoplastic melanoma results in a high pCR rate with acceptable safety profile. Clinicaltrials.gov:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02775851\" ext-link-type=\"uri\">NCT02775851<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s43018-025-01113-y","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:02:14Z","timestamp":1769680934000},"page":"272-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-6689","authenticated-orcid":false,"given":"Kari L.","family":"Kendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay L.","family":"Bellasea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":false,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino K.","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-9755","authenticated-orcid":false,"given":"Alexandra","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hyngstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0071-0534","authenticated-orcid":false,"given":"Andrew S.","family":"Brohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-3320","authenticated-orcid":false,"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawnya","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-5329","authenticated-orcid":false,"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia R.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Baselga-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Perez","family":"Garcilazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Vega-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-9143","authenticated-orcid":false,"given":"Jia Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly Naser Al","family":"Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6570","authenticated-orcid":false,"given":"Michael C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/ng.3382","volume":"47","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194\u20131199 (2015).","journal-title":"Nat. Genet."},{"key":"1113_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature25187","volume":"553","author":"Z Eroglu","year":"2018","unstructured":"Eroglu, Z. et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553, 347\u2013350 (2018).","journal-title":"Nature"},{"key":"1113_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/PAS.0000000000000451","volume":"39","author":"T Wiesner","year":"2015","unstructured":"Wiesner, T. et al. NF1 mutations are common in desmoplastic melanoma. Am. J. Surg. Pathol. 39, 1357\u20131362 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"1113_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/jdv.17154","volume":"35","author":"TM Hughes","year":"2021","unstructured":"Hughes, T. M. et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J. Eur. Acad. Dermatol. Venereol. 35, 1290\u20131298 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1113_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"1113_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655\u20131661 (2018).","journal-title":"Nat. Med."},{"key":"1113_CR8","doi-asserted-by":"crossref","unstructured":"Kendra, K.L. et al. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat. Med. 31, 3668\u20133674 (2025).","DOI":"10.1038\/s41591-025-03875-5"},{"key":"1113_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccell.2023.03.010","volume":"41","author":"KM Campbell","year":"2023","unstructured":"Campbell, K. M. et al. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell 41, 791\u2013806 (2023).","journal-title":"Cancer Cell"},{"key":"1113_CR10","doi-asserted-by":"publisher","first-page":"113530","DOI":"10.1016\/j.ejca.2024.113530","volume":"199","author":"JR Brahmer","year":"2024","unstructured":"Brahmer, J. R. et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur. J. Cancer 199, 113530 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1113_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"1113_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"1113_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"1113_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611, 155\u2013160 (2022).","journal-title":"Nature"},{"key":"1113_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"1113_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861\u20131868 (2018).","journal-title":"Ann. Oncol."},{"key":"1113_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178\u20131188 (2022).","journal-title":"Nat. Med."},{"key":"1113_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","volume":"15","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M., Robert, C. & Ribas, A. The new era of adjuvant therapies for melanoma. Nat. Rev. Clin. Oncol. 15, 535\u2013536 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1113_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.0.CO;2-7","volume":"83","author":"MJ Quinn","year":"1998","unstructured":"Quinn, M. J. et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 83, 1128\u20131135 (1998).","journal-title":"Cancer"},{"key":"1113_CR21","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1002\/cncr.23895","volume":"113","author":"JY Chen","year":"2008","unstructured":"Chen, J. Y. et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 113, 2770\u20132778 (2008).","journal-title":"Cancer"},{"key":"1113_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pathol.2022.12.347","volume":"55","author":"C Lezcano","year":"2023","unstructured":"Lezcano, C. et al. Interobserver agreement in the histopathological classification of desmoplastic melanomas. Pathology 55, 223\u2013226 (2023).","journal-title":"Pathology"},{"key":"1113_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper, C. & Pearson, E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404\u2013413 (1934).","journal-title":"Biometrika"},{"key":"1113_CR24","doi-asserted-by":"crossref","unstructured":"Pintilie, M. Competing Risks: A Practical Perspective (John Wiley and Sons, 2006).","DOI":"10.1002\/9780470870709"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01113-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:03:00Z","timestamp":1772204580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01113-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01113-y","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.K. reports institutional research support from Bristol Myers Squibb and trial support from GlaxoSmithKline, Immunocore, Varian Medical Systems and Merck. Z.E. is on advisory boards for Regeneron, Pfizer, Replimune, Incyte, Natera and SunPharma and receives research funding from Pfizer and Boehringer Ingelheim. S.H.-L. is a scientific advisor\/consultant for Amgen, Ascendis, Astellas, BMS, Genmab, Endeavor, Immunocore, Merck, Nektar, Neon Therapeutics, Novartis, Regeneron, Replimune, Vaccinex and Xencor and contracted research through affiliated institutions with Astellas, Aulos Bio, BioAtla, BMS, Boehringer Ingelheim, Checkmate, Dragonfly, Erasca, F Star, Genentech, Immunocore, Iovance, Kite Pharma, Lyell, Merck, Nektar, Neon Therapeutics, OncoC4, Pfizer, Plexxikon, Vaccinex, Vedanta and Xencor. K.M.C. reports being a shareholder in Geneoscopy and Georgiamune and has received consulting fees from Geneoscopy, PACT Pharma, Tango Therapeutics, Flagship Labs 81, the Rare Cancer Research Foundation, the Jaime Leandro Foundation, Noetik, AME Therapeutics and Georgiamune. D.A.W. reports clinical trial support from Orlucent and Blueprint Medicines. G.K.I. reports institutional research grants\/contracts from Pfizer, Regneron, Replmune, Bicara, Merck, Georgiamune, Obsidian, Immunocore, Iovance and Xencor; serves on advisory boards for Pfizer, Regeneron, Replimune and Obsidian and is a consultant for Pfizer. A.I. reports research funding from Merck. J.H. reports institutional research grants\/contracts from Merck, BMS, Iovance, Lyell, Natera, Skyline and Philogen. A.S.B. is an advisory board member for Deciphera and received research funding from Merck. B.C. serves on advisory boards for Atreca, Regeneron and Treeline Biosciences; is on the data monitoring committee for Servier and SpringWorks Therapeutics and receives clinical trial support from Bristol Myers Squibb, Macrogenics, Infinity Pharmaceuticals, Advenchen Laboratories, Xencor, Compugen, Iovance, RAPT Therapeutics, IDEAYA Biosciences, Ascentage, Atreca, Replimune, InstilBio, Adagene, TriSalus Life Sciences, Kinnate, PTC Therapeutics, Xilio Therapeutics, Kezar Life Sciences, Immunocore, AskGene Pharma, Krystal Bio, Nested Therapeutics, Pierre Fabre, Georgiamune and Immatics. N.I.K. serves on advisory boards for Regeneron, Merck, Replimune, Immunocore, Iovance Biotherapeutics, Novartis, IO Biotech, MyCareGorithm and HUYABIO International; receives travel support from Castle Biosciences and Regeneron; is on the data safety monitoring board for Incyte and AstraZeneca; serves on the scientific advisory board for T-Knife Therapeutics; is on the study steering committees for BMS, Nektar, Regeneron and Replimune; owns common stock in Bellicum Pharmaceuticals and Amarin and receives research funding (to institute) from BMS, Merck, Regeneron, Replimune, GSK, Celgene, Novartis, IDEAYA Biosciences, Modulation Therapeutics and HUYABIO International. J. Markowitz receives research support from Morphogenesis (now TuHURA Biosciences) and Merck. M.M. serves on advisory boards for Merck and Regeneron. T.B. receives institutional research support from Replimune, Genentech, Amgen, Natera and Iovance. S.P.P. receives honoraria from advisory boards, steering committees, data safety monitoring boards or consulting from Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Ideaya, Immatics, IO Biotech, MSD, Novartis, Obsidian, OncoSec, Pfizer, Replimune, Scancell and TriSalus Life Sciences. K.F.G. was employed by Merck from November 2021 to August 2023. V.K.S. is a consultant for Bristol Myers Squibb, Genesis Drug Discovery and Development, Merck, Mural Oncology and Novartis and receives research funding from Neogene Therapeutics, Skyline and Turnstone. E.S. is a consultant for DE Shaw Research and serves on the advisory board for Mallinckrodt Pharmaceuticals. A.R. has received honoraria from consulting for Amgen, Bristol Myers Squibb, Merck, Novartis and Roche-Genentech; is or has been a member of the scientific advisory board; holds stock in Appia, Apricity, Arcus, Compugen, CytomX, ImaginAb, ImmPact, Inspirna, Kite-Gilead, Larkspur, Lyell, Lutris, MapKure, Merus, Synthekine and Tango and has received research funding from Agilent and Bristol Myers Squibb through Stand Up to Cancer (SU2C) and patent royalties from Arsenal Bio. S.L.B., W.E.C., J.A.P., C.M.C., E.M., I.B.-C., C.R.G., K.N., I.P.G., A.V.-C., J.M.C., N.N.A.D., J. Moon and M.C.W. report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}